{
  "source": "PA-Notification-Juxtapid.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1053-13\nProgram Prior Authorization/Notification\nMedication Juxtapid® (lomitapide)\nP&T Approval Date 2/2013, 2/2014, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019, 2/2020,\n2/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nJuxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor indicated as an\nadjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where\navailable, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC),\napolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients\nwith homozygous familial hypercholesterolemia (HoFH). The safety and efficacy of Juxtapid\nhave not been established in patients with hypercholesterolemia who do not have HoFH,\nincluding those with heterozygous familial hypercholesterolemia (HeFH). The effect of Juxtapid\non cardiovascular morbidity and mortality has not been determined.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Juxtapid will be approved based on all of the following criteria:\na. Diagnosis of homozygous familial hypercholesterolemia\n-AND-\nb. Patient is on a low-fat diet\n-AND-\nc. Patient is receiving other lipid-lowering therapy (e.g., statin, LDL apheresis)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Juxtapid will be approved based on all of the following criteria:\na. Patient is on a low-fat diet\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nb. Patient is receiving other lipid-lowering therapy (e.g., statin, LDL apheresis)\n-AND-\nc. Documentation of positive clinical response to Juxtapid therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs ma",
    ".\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and medical necessity may be in place.\n4. Reference:\n1. Juxtapid [package insert]. Cambridge, MA: Amryt Pharmaceuticals; September 2020.\nProgram Prior Authorization/Notification - Juxtapid® (lomitapide)\nChange Control\n2/2013 New program.\n2/2014 Annual Review. Added criterion to initial authorization requiring\npatient to be on a low-fat diet. Added criteria to reauthorization\nrequiring patient to be on a low-fat diet and receiving other lipid-\nlowering therapy.\n2/2015 Annual review with no change to coverage criteria. Updated\nbackground and references.\n2/2016 Annual review. Updated background and references. Changed initial\nauthorization period to align with Kynamro.\n2/2017 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n2/2018 Annual review with no changes to coverage criteria. Updated reference.\n2/2019 Annual review with no changes to coverage criteria.\n2/2020 Annual review with no changes to coverage criteria. Updated reference.\n2/2021 Annual review with no changes to coverage criteria. Updated reference.\n2/2022 Annual review with no changes to coverage criteria.\n2/2023 Annual review with no changes to coverage criteria. Added state\nmandate.\n2/2024 Annual review. Changed initial authorization period to 12 months.\n2/2025 Annual review with no changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}